LEO Pharma Presented Data for Hand Eczema Treatment
New clinical and real-world results show improvements in adults and adolescents using delgocitinib cream.
Updated on Oct. 1, 2026 in Allergies
Live Poll
Should pharmaceutical companies prioritize patient-reported quality of life metrics when evaluating the success of new treatments?
LEO Pharma released findings on its delgocitinib cream for moderate to severe chronic hand eczema at the 35th EADV Congress in Vienna. The data highlighted positive clinical results for adults and significant quality of life improvements for adolescent patients.
Why it matters
Chronic hand eczema imposes significant physical and psychological burdens, including chronic pain and itch that interfere with everyday functioning. These results provide new evidence on the efficacy of topical treatments in managing this condition across different age groups.
In the REACHED study, 28.6% of adult patients reached clear or almost clear skin status after eight weeks. Meanwhile, 27.0% of adolescents reported no remaining impact on their quality of life by Week 16 of the treatment.
The players
LEO Pharma
This is a Denmark-based pharmaceutical company that specializes in medical dermatology treatments.
The details
The DELTA TEEN trial and the REACHED study utilized metrics like the Hand Eczema Symptom Diary and HECSI scores to measure disease severity and patient quality of life. Findings indicated that adolescents experienced reduced itch and pain compared to those using a vehicle cream.
Timeline
Patient enrollment for the REACHED study began on June 6, 2025.
The 35th EADV Congress took place in Vienna from September 30 to October 3, 2026.
The Big Picture
This story follows the research trends presented at the 35th EADV Congress. The findings align with the broader scientific effort to establish standardized benchmarks for evaluating the quality of life impacts of topical dermatological therapies.
Patients with moderate to severe chronic hand eczema may see new treatment options emerging based on these clinical outcomes. These findings could eventually influence how dermatologists prescribe topical creams to address both skin clearance and patient quality of life.
The takeaway
Chronic hand eczema is a persistent condition that significantly impacts daily activities for millions of people. Understanding the efficacy of new treatments helps patients work with their healthcare providers to develop more effective long-term symptom management strategies.
Further reading
For additional context on skin condition management, visit the Allergies section.
Live Poll
Should pharmaceutical companies prioritize patient-reported quality of life metrics when evaluating the success of new treatments?
